How to interpret liver function tests in heart failure patients?

Turkish Journal of Gastroenterology

Volumn 26, Issue 3, 2015, Pages 197-203

  Çaʇli, Kumral ^a   Başar, Fatma Nurcan ^b   Tok, Derya ^a   Turak, Osman ^a   Başar, Ömer ^b  

^a TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Acute cardiogenic liver injury; Cardiac hepatopathy; Congestive hepatopathy

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; BILIRUBIN; CARDIOVASCULAR AGENT; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE; BIOLOGICAL MARKER; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; APIXABAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DABIGATRAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RIVAROXABAN; WARFARIN;

ACUTE CARDIOGENIC LIVER INJURY; ACUTE HEART FAILURE; ACUTE HEART INFARCTION; ADVERSE OUTCOME; APOPTOSIS; CARDIOVASCULAR MORTALITY; CHOLESTASIS; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONGESTIVE HEART FAILURE; CONGESTIVE HEPATOPATHY; CONSTRICTIVE PERICARDITIS; DISEASE ASSOCIATION; DISEASE SEVERITY; ERYTHROCYTE; HEART FAILURE; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; LIVER BLOOD FLOW; LIVER CELL; LIVER DISEASE; LIVER FUNCTION TEST; LIVER INJURY; LIVER NECROSIS; LIVER SINUSOID; MANAGED CARE; MYOCARDITIS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT CARE; PROGNOSIS; PROGNOSTIC ASSESSMENT; REVIEW; TRICUSPID VALVE REGURGITATION; VENOUS CONGESTION; BLOOD; COMPLICATION; INJURIES; LIVER; LIVER DISEASES; NECROSIS; PATHOLOGY; BILIRUBIN BLOOD LEVEL; CARDIAC HEPATOPATHY; CLINICAL FEATURE; ENZYME BLOOD LEVEL; HEART LEFT VENTRICLE EJECTION FRACTION; PREDICTIVE VALUE;

ALKALINE PHOSPHATASE; BILIRUBIN; BIOMARKERS; CHOLESTASIS; GAMMA-GLUTAMYLTRANSFERASE; HEART FAILURE; HUMANS; LACTATE DEHYDROGENASES; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; NECROSIS; PROGNOSIS; TRANSAMINASES;

EID: 84928810959     PISSN: 13004948     EISSN: 21485607     Source Type: Journal    
DOI: 10.5152/tjg.2015.0086     Document Type: Review

References (73)

1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147-239. [CrossRef]
2. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-847. [CrossRef]
3. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013; 127: e6-245. [CrossRef]
4. Heart Failure Society of America, Lindenfeld J, Albert NM, et al. Heart Failure Society of America 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16: e1-194. [CrossRef]
5. Allen LA, Felker GM, Pocock S, et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail 2009; 11: 170-7. [CrossRef]
6. Felker GM, Allen LA, Pocock SJ, et al. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol 2007; 50: 40-7. [CrossRef]
7. de Silva R, Nitikin NP, Witte KK, et al. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J 2006; 27: 569-81. [CrossRef]
8. Damman K, Navis G, Voors AA, et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 2007; 13: 698-700. [CrossRef]
9. Sherlock S. The liver in heart failure; relation of anatomical, functional, and circulatory changes. Br Heart J 1951; 13: 273-93. [CrossRef]
10. Seeto RK, Fenn B, Rockey DC. Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med 2000; 109: 109-13. [CrossRef]
11. Naschitz JE, Slobodin G, Lewis RJ, Zuckerman E, Yeshurun D. Heart diseases affecting the liver and liver diseases affecting the heart. Am Heart J 2000; 140: 111-20. [CrossRef]
12. Nikolaou M, Parissis J, Yilmaz MB, et al. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J 2013; 34: 742-9. [CrossRef]
13. Myers RP, Cerini R, Sayegh R, et al. Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology 2003; 37: 393-400. [CrossRef]
14. Møller S, Bernardi M. Interactions of the heart and the liver. Eur Heart J 2013; 34: 2804-11. [CrossRef]
15. Kavoliuniene A, Vaitiekiene A, Cesnaite G. Congestive hepatopathy and hypoxic hepatitis in heart failure: a cardiologist's point of view. Int J Cardiol 2013; 166: 554-8. [CrossRef]
16. Weisberg IS, Jacobson IM. Cardiovascular diseases and the liver. Clin Liver Dis 2011; 15: 1-20. [CrossRef]
17. Alvarez AM, Mukherjee D. Liver abnormalities in cardiac diseases and heart failure. Int J Angiol 2011; 20: 135-42. [CrossRef]
18. Samsky MD, Patel CB, DeWald TA, et al. Cardiohepatic interactions in heart failure: an overview and clinical implications. J Am Coll Cardiol 2013; 61: 2397-405. [CrossRef]
19. Henrion J. Hypoxic hepatitis. Liver Int 2012; 32: 1039-52. [CrossRef]
20. Giallourakis CC. Liver complications in patients with congestive heart failure. Gastroenterol Hepatol (N Y). 2013; 9: 244-6.
21. Safran AP, Schaffner F. Chronic passive congestion of the liver in man. Electron microscopic study of cell atrophy and intralobular fibrosis. Am J Pathol 1967; 50: 447-63.
22. Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl 2000; 6: S44-52. [CrossRef]
23. Dunn GD, Hayes P, Breen KJ, Schenker S. The liver in congestive heart failure: a review. Am J Med Sci 1973; 265: 174-89. [CrossRef]
24. Valla D. Cirrhosis of vascular origin. Rev Prat 1991; 41: 1170-3.
25. Herzer K, Kneiseler G, Bechmann LP, et al. Onset of heart failure determines the hepatic cell death pattern. Ann Hepatol 2011; 10: 174-9.
26. Seeto RK, Fenn B, Rockey DC. Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med 2000; 109: 109-13. [CrossRef]
27. Cogger VC, Fraser R, Le Couteur DG. Liver dysfunction and heart failure. Am J Cardiol 2003; 91: 1399. [CrossRef]
28. Wanless IR, Liu JJ, Butany J. Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis). Hepatology 1995; 21: 1232-7. [CrossRef]
29. Giallourakis CC, Rosenberg PM, Friedman LS. The liver in heart failure. Clin Liver Dis 2002; 6: 947-67. [CrossRef]
30. Baek JS, Bae EJ, Ko JS, et al. Late hepatic complications after Fontan operation; non-invasive markers of hepatic fibrosis and risk factors. Heart 2010; 96: 1750-5. [CrossRef]
31. Bergman M, Vitrai J, Salman H. Constrictive pericarditis: A reminder of a not so rare disease. Eur J Intern Med 2006; 17: 457-64. [CrossRef]
32. Lebray P, Varnous S, Charlotte F, Varaut A, Poynard T, Ratziu V. Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency. Hepatology 2008; 48: 2089. [CrossRef]
33. Bacon BR, Joshi SN, Granger DN. Ischemia, congestive heart failure, Budd-Chiari Syndrome and veno-occlusive disease. In: Kaplowitz N, editor. Liver and biliary diease. Baltimore: Williams &Wilkins; 1992. p.421-31.
34. Denis C, De Kerguennec C, Bernuau J, Beauvais F, Cohen Solal A. Acute hypoxic hepatitis ('liver shock'): still a frequently overlooked cardiological diagnosis. Eur J Heart Fail 2004; 6: 561-5. [CrossRef]
35. Henrion J, Schapira M, Luwaert R, Colin L, Delannoy A, Heller FR. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore) 2003; 82: 392-406. [CrossRef]
36. Raurich JM, Llompart-Pou JA, Ferreruela M, et al. Hypoxic hepatitis in critically ill patients: incidence, etiology and risk factors for mortality. J Anesth 2011; 25: 50-6. [CrossRef]
37. Fauci AS, Braunwald E, Hauser SL, Longo DL, Jameson J, Loscalzo J. Harrison's Principles of Internal Medicine. Vol 2. New York, NY: McGraw-Hill Medical, 2008.
38. Kavoliuniene A, Vaitiekiene A, Cesnaite G. Congestive hepatopathy and hypoxic hepatitis in heart failure: a cardiologist's point of view. Int J Cardiol 2013; 166: 554-8. [CrossRef]
39. van Lingen R, Warshow U, Dalton HR, Hussaini SH. Jaundice as a presentation of heart failure. J R Soc Med 2005; 98: 357-9. [CrossRef]
40. Vasconcelos LA, de Almeida EA, Bachur LF. Clinical evaluation and hepatic laboratory assessment in individuals with congestive heart failure. Arq Bras Cardiol 2007; 88: 590-5. [CrossRef]
41. Lau GT, Tan HC, Kritharides L. Type of liver dysfunction in heart failure and its relation to the severity of tricuspid regurgitation. Am J Cardiol 2002; 90: 1405-9. [CrossRef]
42. van Deursen VM, Damman K, Hillege HL, van Beek AP, van Veldhuisen DJ, Voors AA. Abnormal liver function in relation to hemodynamic profile in heart failure patients. J Card Fail 2010; 16: 84-90. [CrossRef]
43. Poelzl G, Eberl C, Achrainer H, et al. Prevalence and prognostic significance of elevated gamma-glutamyltransferase in chronic heart failure. Circ Heart Fail 2009; 2: 294-302. [CrossRef]
44. Kubo SH, Walter BA, John DH, Clark M, Cody RJ. Liver function abnormalities in chronic heart failure. Influence of systemic hemodynamics. Arch Intern Med 1987; 147: 1227-30. [CrossRef]
45. Ess M, Mussner-Seeber C, Mariacher S, et al. γ-Glutamyltransferase rather than total bilirubin predicts outcome in chronic heart failure. J Card Fail 2011; 17: 577-84. [CrossRef]
46. Batin P, Wickens M, McEntegart D, Fullwood L, Cowley AJ. The importance of abnormalities of liver function tests in predicting mortality in chronic heart failure. Eur Heart J 1995; 16: 1613-8.
47. Poelzl G, Ess M, Mussner-Seeber C, Pachinger O, Frick M, Ulmer H. Liver dysfunction in chronic heart failure: prevalence, characteristics and prognostic significance. Eur J Clin Invest 2012; 42: 153-63. [CrossRef]
48. Matthews JC, Koelling TM, Pagani FD, Aaronson KD. The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. J Am Coll Cardiol 2008; 51: 2163-72. [CrossRef]
49. Singh TP, Almond CS, Semigran MJ, Piercey G, Gauvreau K. Risk prediction for early in-hospital mortality following heart transplantation in the United States. Circ Heart Fail 2012; 5: 259-66. [CrossRef]
50. Chokshi A, Cheema FH, Schaefle KJ, et al. Hepatic dysfunction and survival after orthotopic heart transplantation: application of the MELD scoring system for outcome prediction. J Heart Lung Transplant 2012; 31: 591-600. [CrossRef]
51. Sheer TA, Joo E, Runyon BA. Usefulness of serum N-terminal-ProBNP in distinguishing ascites due to cirrhosis from ascites due to heart failure. J Clin Gastroenterol 2010; 44: e23-6. [CrossRef]
52. Kisloff B, Schaffer G. Fulminant hepatic failure secondary to congestive heart failure. Am J Dig Dis 1976; 21: 895-900. [CrossRef]
53. Taylor RM, Tujios S, Jinjuvadia K, et al. Short and long-term outcomes in patients with acute liver failure due to ischemic hepatitis. Dig Dis Sci 2012; 57: 777-85. [CrossRef]
54. Saner FH, Heuer M, Meyer M, et al. When the heart kills the liver: acute liver failure in congestive heart failure. Eur J Med Res 2009; 14: 541-6.
55. Henrion J, Descamps O, Luwaert R, Schapira M, Parfonry A, Heller F. Hypoxic hepatitis in patients with cardiac failure: incidence in a coronary care unit and measurement of hepatic blood flow. J Hepatol 1994; 21: 696-703. [CrossRef]
56. Hickman PE, Potter JM. Mortality associated with ischaemic hepatitis. Aust N Z J Med 1990; 20: 32-4. [CrossRef]
57. Naschitz JE, Yeshurun D. Compensated cardiogenic shock: a subset with damage limited to liver and kidneys. The possible salutary effect of low-dose dopamine. Cardiology 1987; 74: 212-8. [CrossRef]
58. Fuhrmann V, Kneidinger N, Herkner H, et al. Hypoxic hepatitis: underlying conditions and risk factors for mortality in critically ill patients. Intensive Care Med 2009; 35: 1397-405. [CrossRef]
59. Cassidy WM, Reynolds TB. Serum lactic dehydrogenase in the differential diagnosis of acute hepatocellular injury. J Clin Gastroenterol 1994; 19: 118-21. [CrossRef]
60. Ambrosy AP, Vaduganathan M, Huffman MD, et al. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. Eur J Heart Fail 2012; 14: 302-11. [CrossRef]
61. Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013; 61: 196-206. [CrossRef]
62. Hasper D, Jörres A. New insights into the management of hepato-renal syndrome. Liver Int 2011; 31: 27-30. [CrossRef]
63. Kisloff B, Schaffer G. Fulminant hepatic failure secondary to congestive heart failure. Am J Dig Dis 1976; 21: 895-900. [CrossRef]
64. Verbrugge FH, Dupont M, Steels P, et al. Abdominal contributions to cardiorenal dysfunction in congestive heart failure. J Am Coll Cardiol 2013; 62: 485-95. [CrossRef]
65. Mullens W, Abrahams Z, Francis GS, Taylor DO, Starling RC, Tang WH. Prompt reduction in intra-abdominal pressure following large-volume mechanical fluid removal improves renal insufficiency in refractory decompensated heart failure. J Card Fail 2008; 14: 508-14. [CrossRef]
66. Bansal S, Lindenfeld J, Schrier RW. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail 2009; 2: 370-6. [CrossRef]
67. Russell SD, Rogers JG, Milano CA, et al. Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the HeartMate II left ventricular assist device. Circulation 2009; 120: 2352-7. [CrossRef]
68. Cannon RM, Hughes MG, Jones CM, Eng M, Marvin MR. A review of the United States experience with combined heart-liver transplantation. Transpl Int 2012; 25: 1223-8. [CrossRef]
69. Sokol SI, Cheng A, Frishman WH, Kaza CS. Cardiovascular drug therapy in patients with hepatic diseases and patients with congestive heart failure. J Clin Pharmacol 2000; 40: 11-30. [CrossRef]
70. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008; 64: 1147-61. [CrossRef]
71. Ferreira J, Ezekowitz MD, Connolly SJ, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. Eur J Heart Fail 2013; 15: 1053-61. [CrossRef]
72. McMurray JJ, Ezekowitz JA, Lewis BS, et al. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail 2013; 6: 451-60. [CrossRef]
73. van Diepen S, Hellkamp AS, Patel MR, et al. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circ Heart Fail 2013; 6: 740-7. [CrossRef]